Our study showed that patients from PAH-CHD, CTEPH, and iPAH subsets had a significantly higher percentage of CD200-positive CD4+ and CD8+ T-cells than controls. The gene discussed is CD4; the disease is chronic thromboembolic pulmonary hypertension.